We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pradaxa Wins FDA Panel’s Approval, to Compete With Generic Coumadin
Pradaxa Wins FDA Panel’s Approval, to Compete With Generic Coumadin
September 28, 2010
Manufacturers of Bristol-Myers Squibb’s Coumadin are likely to see increased competition to their drugs now that an FDA advisory committee has given a unanimous approval recommendation to Boehringer Ingelheim’s anticoagulant Pradaxa.